ABSTRACT
Background The first six months after antiretroviral therapy (ART) initiation for HIV is a high-risk period for treatment interruptions that may compromise viral suppression (VS). Recent research in South Africa suggests that >40% of patients interrupt care for >28 days during the early treatment period. The quantitative association between early treatment interruptions and VS at 6 and 12 months remains unclear.
Methods We enrolled adults (≥18 years) initiating ART from 1 January 2018 to 7 November 2024 with at least 14 months’ followup in South Africa’s national ART database (TIER.Net) from 24 public sector facilities in four provinces. Engagement in care during months 0-6 and 7-12 was classified as continuous (no interruptions >28 days), cyclical (at least one interruption >28 days but returned to care within follow up period), or disengaged (>28 days late without return), based on completed and scheduled visit dates. Modified Poisson regression was used to estimate adjusted risk ratios (aRRs) for VS (<50 copies/mL), adjusting for age, sex, initiation year, regimen, engagement pattern, and baseline CD4 count.
Findings Among 57,553 participants (66% female; median age 33 years), 49% and 42% were continuously engaged at 6 and 12 months, respectively; 22% and 17% were cyclically engaged at the same time points. 54% of continuously engaged participants achieved 6-month VS compared with 34% of those with cyclical engagement (aRR 1.60 95% CI 1.55-1.64). At 12 months, 56% of continuously engaged individuals and 40% of those cyclically engaged were suppressed (aRR 1.38 95% CI 1.34-1.42). VS was also associated with dolutegravir-based regimens, later ART initiation year, baseline CD4 count ≥200 cells/uL, female sex, and older age.
Interpretation Even relatively brief treatment interruptions during the first year of ART were associated with substantially lower viral suppression. Preventing early interruptions should remain a programmatic priority to improve treatment outcomes.
Funding Funding for this study was provided by the Gates Foundation under INV-031690 to Boston University.
Competing Interest Statement
The authors have declared no competing interest.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The IRB of Boston University gave ethical approval for this work (H-38115). The Human Research Ethics Committee of the University of the Witwatersrand gave ethical approval for this work (M190445).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Mariet Benade, mbenade{at}bu.edu; Mhairi Maskew, mmaskew{at}heroza.org; Nyasha Mutanda, nmutanda{at}heroza.org; Nancy Scott, nscott{at}bu.edu; Allison Morgan, juntunen{at}bu.edu; Vinolia Ntjikelane, vntjikelane{at}heroza.org; Linda Sande, lsande{at}heroza.org; Lufuno Malala, lufuno.malala{at}health.gov.za; Musa Manganye, Musa.Manganye{at}health.gov.za; Brooke Nichols, brooken{at}bu.edu
Data availability
Data used in this study are owned by the South Africa National Department of Health and cannot be shared by the authors. Data can be requested through the National Health Research Database at https://nhrd.health.gov.za/ and contacting each province’s representative as shown.
Funder Information Declared
